Pembrolizumab (Pembro) Plus Olaparib In Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Update Of Keynote-365 Cohort A With A Minimum Of 11 Months Of Follow-Up For All Patients
ANNALS OF ONCOLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要